07:00 , Oct 17, 2005 |  BioCentury  |  Strategy

A new Celling proposition

After pulling its planned IPO in August, Celldex Therapeutics Inc. decided to focus on company building by acquiring a pair of smaller companies that also are working on monoclonal antibodies and therapeutic vaccines. Each deal...
07:00 , Oct 17, 2005 |  BC Week In Review  |  Company News

Alteris, Celldex, Lorantis deal

In two separate deals, therapeutic vaccines company Celldex acquired Lorantis for 6.8 million shares and the assets of Alteris for 1.2 million shares, $1.5 million in cash and milestones and other payments. Lorantis' lead program...
00:50 , Oct 14, 2005 |  BC Extra  |  Company News

Celldex acquires Lorantis, Alteris

In two separate deals, therapeutic vaccines company Celldex (Bloomsbury, N.J.) acquired Lorantis (Cambridge, U.K.) for 6.8 million shares and the assets of Alteris (Philadelphia, Penn.) for 1.2 million shares, $1.5 million in cash and milestones...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Clinical News

ALT-110: Phase I data

In an open-label, U.S. Phase I trial in 16 patients with malignant glioma, ALT-110 treatment doubled the time-to-disease progression and increased patient survival compared to historical controls. More than one-quarter of treated patients did not...
08:00 , Dec 6, 2004 |  BC Week In Review  |  Clinical News

ALT-110: Started Phase II

Alteris began an open-label, U.S. Phase I trial in up to 38 patients. Alteris Therapeutics , Philadelphia, Penn.   Product: ALT-110   Business: Cancer   Molecular target: Epidermal growth factor (EGF) receptor   Description: A...
08:00 , Feb 23, 2004 |  BC Week In Review  |  Company News

Alteris Therapeutics Inc., Duke University Medical Center, Johns Hopkins University deal

Alteris licensed from the universities additional rights to its lead product, ALT-110 . The compound is a therapeutic vaccine targeting EGFRvIII , a tumor-specific splice variant of the epidermal growth factor receptor (EGFR) . The...